53902-93-5

Usage

Uses

Used in Organic Synthesis:
3-bromopyrazolo[1,5-a]pyrazine is used as a building block in organic synthesis for creating more complex molecules. Its unique structure and reactivity make it a valuable tool for chemists and researchers in this field.
Used in Pharmaceutical Research:
In pharmaceutical research, 3-bromopyrazolo[1,5-a]pyrazine is used as a precursor to develop new drugs. Its properties allow it to be a key component in the discovery and development of novel pharmaceuticals.
Used in Electronics and Optoelectronics Materials Development:
3-bromopyrazolo[1,5-a]pyrazine has potential applications in the development of materials for electronics and optoelectronics industries. Its interesting electronic and optical properties make it a promising candidate for advancing technologies in these fields.

Upstream product

• 1219694-61-7 ethyl pyrazolo[1,5-a]pyrazine-3-carboxylate 
• 53902-76-4 pyrazolo[1,5-a]pyrazine-3-carboxylic acid 

Relevant academic research and scientific papers

A Flexible Strategy for the Regiocontrolled Synthesis of Pyrazolo[1,5-a]pyrazines

A four-step protocol for the synthesis of pyrazolo[1,5-a]pyrazines has been developed. Commercially available pyrazoles were alkylated and formylated in a regiocontrolled manner to give pyrazole-5-aldehydes bearing 2,2-dialkoxyethyl substitution on N-1. Efficient conditions for the subsequent deprotection and cyclization of these intermediates allowed access to pyrazolo[1,5-a]pyrazines with multiple substitution patterns. The versatility of the pyrazole-5-aldehyde intermediates was further demonstrated through a deprotection and double-reductive amination sequence to give 4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazines.

Heteroaryl imidazolone derivatives as jak inhibitors

New heteroaryl imidazolone derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).

HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS

New heteroaryl imidazolone derivatives having the chemical structure of formula (I) disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).

PYRAZOLE DERIVATIVES AS JAK INHIBITORS

New pyrazole derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).